BiotechTube

Refacto AF

Pre-clinicalWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Sep 1, 2019 → Jan 1, 2022

NCT ID
NCT02718677

About Refacto AF

Refacto AF is a pre-clinical stage product being developed by Pfizer for Hemophilia A. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02718677. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (3) Active (0)
✅EmicizumabRocheApproved
✅BenefixPfizerApproved
✅Nonacog alfaPfizerApproved
✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved
✅Recombinant Factor IX CoagulationPfizerApproved
✅Moroctocog alfa(AF-CC)PfizerApproved
✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00038935Phase 3Completed
NCT00037544Phase 3Completed
NCT02718677Pre-clinicalWithdrawn
NCT00243659Phase 3Completed

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
EmicizumabChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
SPK-8011QQRochePhase 1/2
39
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40
Nonacog alfa + Nonacog alfaPfizerPhase 3
40